Putting chirality to work: the strategy of chiral switches

摘要: Most of the new drugs reaching market today are single enantiomers, rather than racemic mixtures that dominated up to ten years ago. Many single-enantiomer were developed as such, but there also important examples derived from 'chiral switches' established racemates. Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability 'line extension' major drug with patents expiring.